Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of olmesartan medoxomil + levamlodipine fixed-dose combination in adults with mild-to-moderate essential hypertension uncontrolled after 4 weeks of olmesartan or amlodipine monotherapy
CTR20242837Phase 3Active
- Sponsor
- Jiangxi Shimei Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olmesartan and Levamlodipine in essential hypertension (2 arms), sponsored by Jiangxi Shimei Pharmaceutical. Primary endpoint: Change from baseline in trough seated diastolic blood pressure after 8 weeks of randomized double-blind treatment. Started Oct 2024; status: active.
02
Drugs
olmesartanLevamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20242837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242837.